0.7499

8.65% -0.071

After Hours: .7688 0.0189 +2.52%

Eyenovia Inc (EYEN)

Overview News Price History Option Chain Financials Discussions Forecast

Eyenovia Inc stock is currently priced at $0.7499, with a 24-hour trading volume of 1.01M. It has seen a -8.65% decreased in the last 24 hours and a +39.05% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.8403 pivot point. If it approaches the $0.7403 support level, significant changes may occur.

Previous Close:

$0.8209

Open:

$0.8221

24h Volume:

1.01M

Market Cap:

$38.21M

Revenue:

Net Income/Loss:

$-27.26M

P/E Ratio:

-1.0868

EPS:

-0.69

Net Cash Flow:

$-27.81M

1W Performance:

-2.77%

1M Performance:

+39.05%

6M Performance:

-44.04%

1Y Performance:

-78.99%

1D Range:

$0.7498

$0.8699

52W Range:

$0.501

$3.59

Eyenovia Inc Stock (EYEN) Company Profile

Name

Eyenovia Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

917-289-1117

Address

501 Fifth Avenue, Suite 1404, New York, NY

Employee

Twitter

@eyenovia

Next Earnings Date

2024-06-12

Latest SEC Filings

EYEN's Discussions on Twitter

Eyenovia Inc Stock (EYEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-01-21	Initiated	Northland Capital	Outperform
Feb-03-20	Downgrade	Oppenheimer	Outperform → Perform

Eyenovia Inc Stock (EYEN) Latest News

Eyenovia, Inc. (NASDAQ:EYEN) Q1 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

EYEN Stock Sees Surge of Approximately 22.54% in Last Five Days – Knox Daily - Knox Daily

Knox Daily

Eyenovia (NASDAQ:EYEN) Given Buy Rating at HC Wainwright - MarketBeat

MarketBeat

Earnings call: Eyenovia reports Q1 2024 results, focuses on product pipeline - Investing.com Australia

Investing.com Australia

Earnings call: Eyenovia reports Q1 2024 results, focuses on product pipeline - Investing.com South Africa

Investing.com South Africa

Earnings call: Eyenovia reports Q1 2024 results, focuses on product pipeline By Investing.com - Investing.com

Investing.com

Eyenovia Inc Stock (EYEN) Financials Data

Eyenovia Inc (EYEN) Net Income 2024

EYEN net income (TTM) was -$27.26 million for the quarter ending December 31, 2023, a +2.68% increase year-over-year.

Eyenovia Inc (EYEN) Cash Flow 2024

EYEN recorded a free cash flow (TTM) of -$27.81 million for the quarter ending December 31, 2023, a -7.03% decrease year-over-year.

Eyenovia Inc (EYEN) Earnings per Share 2024

EYEN earnings per share (TTM) was -$0.65 for the quarter ending December 31, 2023, a +22.62% growth year-over-year.

Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.